Therapeutic effects of Baicalein on atopic dermatitis-like skin lesions of NC/Nga mice induced by dermatophagoides pteronyssinus.
The present study was conducted to investigate the effects of Baicalein (BE), which is hydrolyzed product of Baicalin (BA), on atopic dermatitis (AD). AD was induced in NC/Nga mice by DPE treatment. BE hydrogels treatment reduced the levels of skin severity scores. BE hydrogels treatment also decreased inflammatory cytokines such as TNF-alpha, IL-6, and its level in the serum. BE hydrogels treatment elevated IFN-gamma level in the spleenocyte culture supernatant. Cell numbers in the skin positive to CD3+/CD69+, CCR3+, CD11b+/Gr-1+, B220+/IgE+ all of which were up-regulated in AD-induced mice were decreased and returned to normal levels. Histological examination showed that infiltration levels of immune cells in the skin of AD-induced NC/Nga mice were much improved by BE hydrogels treatment. These results thus suggest that BE can regulate molecular mediators and immune cells that are functionally associated with atopic dermatitis induced in NC/Nga mice, and may play an important role in recovering AD symptoms.
Yun
Mi-Young
MY
Department of Health Welfare, Byuksung College, Gimje 576-711, Republic of Korea.
Yang
Jae-Heon
JH
Kim
Dae-Keun
DK
Cheong
Kwang-Jo
KJ
Song
Hyang-Hee
HH
Kim
Dong-Hee
DH
Cheong
Kyu-Jin
KJ
Kim
Young-Il
YI
Shin
Sang-Chul
SC
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000032:analysis / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis / Q000276:immunology; D018845:CD11 Antigens / Q000032:analysis / Q000276:immunology; D017252:CD3 Complex / Q000032:analysis / Q000276:immunology; D002478:Cells, Cultured; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D040002:Dermatophagoides pteronyssinus / Q000276:immunology*; D005260:Female; D044950:Flavanones / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D007073:Immunoglobulin E / Q000032:analysis / Q000276:immunology; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D018836:Inflammation Mediators / Q000032:analysis / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D015850:Interleukin-6 / Q000097:blood / Q000276:immunology; D037181:Lectins, C-Type / Q000032:analysis / Q000276:immunology; D017493:Leukocyte Common Antigens / Q000032:analysis / Q000276:immunology; D051379:Mice; D054397:Receptors, CCR3 / Q000032:analysis / Q000276:immunology; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000276:immunology; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology; D000099192:CD69 Antigens
D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018845:CD11 Antigens; D017252:CD3 Complex; D044950:Flavanones; D007073:Immunoglobulin E; D018836:Inflammation Mediators; D007371:Interferon-gamma; D015850:Interleukin-6; D037181:Lectins, C-Type; D017493:Leukocyte Common Antigens; D054397:Receptors, CCR3; D014409:Tumor Necrosis Factor-alpha; D000099192:CD69 Antigens; C515351:Ccr3 protein, mouse; C006680:baicalein